COSITECAN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C25H28N2O4Si
Molecular Weight	448.5863
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC[C@@]1(O)C(=O)OCC2=C1C=C3N(CC4=C3N=C5C=CC=CC5=C4CC[Si](C)(C)C)C2=O

InChI

InChIKey=POADTFBBIXOWFJ-VWLOTQADSA-N

InChI=1S/C25H28N2O4Si/c1-5-25(30)19-12-21-22-17(13-27(21)23(28)18(19)14-31-24(25)29)15(10-11-32(2,3)4)16-8-6-7-9-20(16)26-22/h6-9,12,30H,5,10-11,13-14H2,1-4H3/t25-/m0/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11004678 | https://adisinsight.springer.com/drugs/800011000 | https://www.ncbi.nlm.nih.gov/pubmed/17854432

Cositecan (BNP1350) is semi-synthetic silicon-containing camptothecin and an inhibitor of topoisomerase I. It was engineered by BioNumerik Pharmaceuticals for superior oral bioavailability, lactone stability, and insensitivity to Pgp/MRP/LRP drug resistance. The compound shows a broad spectrum of activity in experimental human tumors. Cositecan was investigated in clinical trials in patients with malignant melanoma, relapsed or refractory non-small cell lung cancer, ovarian and peritoneal cancer, malignant glioma. The compound had little activity in recurrent glioma and ovarian cancer.

Originator

Approval Year

PubMed

Title	Date	PubMed

Name

Type

Language

COSITECAN

Official Name

English

BNP-1350

Code

English

KARENITECIN

Brand Name

English

cositecan [INN]

Common Name

English

1H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-3,14(4H,12H)-DIONE, 4-ETHYL-4-HYDROXY- 11-(2- (TRIMETHYLSILYL)ETHYL)-, (4S)-

Common Name

English

COSITECAN [USAN]

Common Name

English

(4S)-4-ETHYL-4-HYDROXY-11-(2-(TRIMETHYLSILYL)ETHYL)-1,12-DIHYDRO-14H- PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-3,14(4H)-DIONE

Systematic Name

English

Cositecan [WHO-DD]

Common Name

English

COSITECAN [MI]

Common Name

English

BNP1350

Code

English

KARENTECIN

Brand Name

English

Code System Code Type Description

INN

9037